Processa Pharmaceuticals, Inc. - 8-K Filing
Processa Pharmaceuticals appoints Dr. Sheila Gujrathi as Executive Chair and announces FDA IND clearance for VT-7208 Phase 2 study. (Items: 8.01 Other Events On October 27, 2026, Justin Yorke resigned as chair of the board of directors (the “Board”) of Processa Pharmaceuticals, Inc, 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit Number Description 99)
Tickers: $PCSA